Thursday 18th February 2021 It is important for primary care practitioners to explore and assess peripheral neuropathy carefully by evaluating the level of impact on the patient, both physically and emotionally. Many individuals receiving chemotherapy are nervous...
Potential pitfall: Irritable bowel syndrome (IBS) is a common disorder and can mimic the symptoms of ovarian cancer. Helpful hint: NICE NG12 guidelines recommend carrying out appropriate tests for ovarian cancer in any woman of 50 or over who has experienced symptoms...
4th February 2021 The 4th of February 2021 marks World Cancer Day 2021. This year, the theme #IAmAndIWill encourages us to recognise our own commitments to improving cancer outcomes. GatewayC now has over 19 free online cancer education courses which can help primary...
29th January 2021 Missed our free GatewayC LIVE webinar? Watch our recording here. In this webinar, GatewayC met Professor Robert Duncombe, Director of Pharmacy at The Christie NHS Foundation Trust and Dr Neil Bayman, Consultant Clinical Oncologist and Associate...
Monoclonal gammopathy of undetermined significance (MGUS) is a benign condition characterised by the presence of paraproteins in the blood and/or urine. It doesn’t cause symptoms or require treatment and is usually only diagnosed when patients are investigated for other issues.
While most people with MGUS will not see an effect on their general health, about 1% of patients with MGUS will go on to develop myeloma each year.
The GatewayC Myeloma – Early Diagnosis course explores MGUS and its relationship with Myeloma in greater detail. GatewayC’s Cancer Lead GP, Dr. Sarah Taylor discusses the significance of this pre-malignant condition with Dr. Neil Rabin, Consultant Haematologist at University College London Hospitals and North Middlesex University Hospital NHS Trust.
MGUS is a condition which resembles myeloma due to the presence of abnormal plasma cells in the bone marrow and paraprotein in the blood and/or urine, but at much lower levels than in myeloma.
Each year around one in 100 MGUS patients will be diagnosed with myeloma and will need treatment. MGUS usually remains stable for many years without progressing to myeloma. Data suggests that if MGUS remains stable for two years then, on average, it will remain stable for 10 years before there is progression to myeloma.*
The presence of paraproteins in a patient’s blood or urine doesn’t necessarily mean they have myeloma and could be indicative of MGUS. However, it is important that these patients are sent to a haematologist, so that they can be appropriately investigated and be given advice on what symptoms to look out for.
Find out more: visit the GatewayC Myeloma – Early Diagnosis course here.
* Information from Myeloma UK – MGUS. See link here.
Thursday 18th February 2021 It is important for primary care practitioners to explore and assess peripheral neuropathy carefully by evaluating the level of impact on the patient, both physically and emotionally. Many individuals receiving chemotherapy are nervous...
Potential pitfall: Irritable bowel syndrome (IBS) is a common disorder and can mimic the symptoms of ovarian cancer. Helpful hint: NICE NG12 guidelines recommend carrying out appropriate tests for ovarian cancer in any woman of 50 or over who has experienced symptoms...
4th February 2021 The 4th of February 2021 marks World Cancer Day 2021. This year, the theme #IAmAndIWill encourages us to recognise our own commitments to improving cancer outcomes. GatewayC now has over 19 free online cancer education courses which can help primary...
29th January 2021 Missed our free GatewayC LIVE webinar? Watch our recording here. In this webinar, GatewayC met Professor Robert Duncombe, Director of Pharmacy at The Christie NHS Foundation Trust and Dr Neil Bayman, Consultant Clinical Oncologist and Associate...